Eyeliner application may cause vision problems: study

April 2, 2015

Toronto, Apr 2: Women who apply eyeliner on the inner eyelid run the risk of contaminating the eye and causing vision trouble, a new study has warned.

This is the first study to prove that particles from pencil eyeliner move into the eye.

EyelinerResearchers used video recordings to observe and compare the amount of eyeliner particles that migrated into the tear film - the thin coating protecting the eye - after applying makeup in different styles.

“We noticed that the makeup migration happened quicker and was greater when eyeliner was put on the inner lid margin,” said Alison Ng, a scientist at the University of Waterloo.

Each participant wore glitter eyeliner outside the lash line, and then on the inner lid area closer to the eye, or along the waterline.

The vision scientists found that within five minutes, between 15 and 30 per cent more particles moved into the eye’s tear film when subjects applied eyeliner to the inside of the lash line, compared to outside it.

The makeup also moved more quickly into the eye when eyeliner was applied inside the lash line.

As time passes, the amount of makeup entering the tear film steadily drops and by two hours, there was a negligible amount of eyeliner left.

However, Ng, who directed the study when she was at Cardiff University in Wales, and her colleagues say eyeliner can alter the tear film, adding to discomfort.

Eyeliner ingredients

Eyeliner ingredients commonly include waxes, oils, silicones and natural gums to help eyeliner stick to eyelids and last for prolonged periods. It has to adhere through blinking, sweating and the secretion of natural oils.

Makeup that enters the tear film may cause discomfort for those with sensitive or dry eyes. But the eyeliner waxes and oils can also adhere to contact lenses and build up if used for more than one day.

Resulting complications include irritation and redness, introduction of harmful bacteria from the eyeliner, and in some cases, eye infections or blurred vision.

“People who wear contact lenses are most likely to notice some problems,” said Ng.

“If they have eyeliner stuck to their lenses, increasing deposits might cause vision disruption as the lens becomes cloudier,” said Ng.

While this study did not examine the bacterial aspect of makeup contamination to the eye, Ng notes that previous studies do show that old eye makeup can harbour bacteria.

“If you thoroughly sharpen your pencil eyeliner before each application and get rid of the stuff that’s stuck to the end, you’ll have a fresh tip which can help prevent infection,” said Ng.

“With twist-up eyeliner, cut some off the end before each use. And always make sure to fully remove eye makeup before bed,” Ng added.

The findings appear in the journal Eye and Contact Lens Science and Clinical Practice.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
June 4,2020

The World Health Organisation on Wednesday said that anti-malarial drug hydroxychloroquine (HCQ) will return to the solidarity trial for the potential treatment of coronavirus disease.

At a press conference in the WHO headquarters in Geneva, Director General Tedros Adhanom Ghebreyesus said: "On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol. The Executive Group received this recommendation and endorsed continuation of all arms of the solidarity trial, including hydroxychloroquine."

The world health body had temporarily suspended the usage of HCQ from the solidarity trial for coronavirus treatment on May 25 soon after a study published in one of the most reliable medical journals, which had suggested that the drug could cause more fatalities among COVID-19 patients.

However, the WHO chief said that the decision was taken as a precaution while the safety data was reviewed.

Ghebreyesus also said that the Data Safety and Monitoring Committee will continue to closely monitor the safety of all therapeutics being tested in the solidarity trial.

"So far, more than 3,500 patients have been recruited in 35 countries. WHO is committed to accelerating the development of effective therapeutics, vaccines and diagnostics as part of our commitment to serving the world with science, solutions and solidarity," he said.

Soon after HCQ was suspended from the trial, the Indian government had said that the antimalarial drug has been known for its benefits for a long time and its usage will be continued on the frontline workers, including police and healthcare professionals, as prophylaxis. The government had also said that studies were being conducted and the drug would be included in the clinical trial also for the treatment of coronavirus disease.

US President Donald Trump also had strongly advocated the use of HCQ and called it a "game-changer". He went to the extent of saying that he had taken the medicine.

Launched by WHO and partners, solidarity trial is an international clinical trial to find an effective treatment for COVID-19, including drugs to slow the progression of the disease or improve survival. The trial, which enrols patients from different countries, "will compare four treatment options against standard of care to assess their relative effectiveness against COVID-19", said WHO. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 4,2020

Despite tremendous advances in treatment of congenital heart disease (CHD), a new global study shows that the chances for a child to survive a CHD diagnosis is significantly less in low-income countries.

The research revealed that nearly 12 million people are currently living with CHD globally, 18.7 per cent more than in 1990.

The findings, published in The Lancet, is drawn from the first comprehensive study of congenital heart disease across 195 countries, prepared using data from the Global Burden of Diseases, Injuries and Risk Factors Study 2017 (GBD).

"Previous congenital heart estimates came from few data sources, were geographically narrow and did not evaluate CHD throughout the life course," said the study authors from Children's National Hospital in the US.

This is the first time the GBD study data was used along with all available data sources and previous publications - making it the most comprehensive study on the congenital heart disease burden to date.

The study found a 34.5 per cent decline in deaths from congenital disease between 1990 to 2017. Nearly 70 per cent of deaths caused by CHD in 2017 (180,624) were in infants less than one year old.

Most CHD deaths occurred in countries within the low and low-middle socio-demographic index (SDI) quintiles.

Mortality rates get lower as a country's Socio-demographic Index (SDI) rises, the study said.

According to the researchers, birth prevalence of CHD was not related to a country's socio-demographic status, but overall prevalence was much lower in the poorest countries of the world.

This is because children in these countries do not have access to life saving surgical services, they added.

"In high income countries like the United States, we diagnose some heart conditions prenatally during the 20-week ultrasound," said Gerard Martin from Children's National Hospital who contributed to the study.

"For children born in middle- and low-income countries, these data draw stark attention to what we as cardiologists already knew from our own work in these countries -- the lack of diagnostic and treatment tools leads to lower survival rates for children born with CHD," said researcher Craig Sable.

"The UN has prioritised reduction of premature deaths from heart disease, but to meet the target of 'ending preventable deaths of newborns and children under 5 years of age,' health policy makers will need to develop specific accountability measures that address barriers and improve access to care and treatment," the authors wrote.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.